In Vitro and In Vivo Test of Boron Delivery Agent for Boron Neutron Capture Therapy

Sista Dyah Wijaya¹, Bagaswoto Poedjomartono² and Yohannes Sardjono³
¹Pharmaceutical Science and Technology, School of Pharmacy, Bandung Institute of Technology
²Department of Radiology, Radionuclear Services, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada
³Centre for Accelerator and Science Technology, National Nuclear Energy Agency Indonesia

ARTICLE INFO

Article history:
Received: 14 August 2018
Received in revised form: 1 June 2019
Accepted: 30 June 2019

Keywords:
In vivo
In vitro
Boron delivery agent
BNCT
clinical studies

ABSTRACT

BNCT is an alternative therapy for treating cancer. The principle of BNCT involves a neutron boron capture and a nuclear reaction that produce alpha particle and Li ion with a high level of linear energy transfer in the tissue. It is effective in killing tumor cells. To administer boron in the tumor cells, a boron delivery agent is needed. Thus far, there are a variety of boron delivery agents that have been developed. To date, just two main boron-based drugs, BPA and BSH, have been used for clinical studies. Many other boron delivery agents have been evaluated in vivo and in vitro but have not been evaluated clinically. Therefore, the other boron delivery agents have not been used in BNCT clinical studies.

© 2019 IJPNA. All rights reserved.

1. INTRODUCTION

Cancer is a disease which abnormal cells grow out of control and affect different organs. Cancer can spread to any organs. In 2018, there were 9.6 million deaths in the world caused by cancer. The most common organs that are infected by cancer are the lungs, breasts, colon, prostate, skin, and stomach. The types of cancer treatments that exist are surgery, chemotherapy, radiotherapy, hormone therapy, targeted therapy, and immunotherapy. For some people, there are many side effects after receiving a treatment for cancer including nausea and fatigue [1,2]. To minimize side effects from the treatment of cancer, researchers have been considering called an alternative of therapy cancer that can selectively destroy cancer cells and spare normal cells [3].

Boron neutron capture therapy (BNCT) is a binary therapy for healing cancer [4]. The principle mechanisms of BNCT are nuclear uptake and fission reaction. In BNCT, boron ($^{10}$B) that accumulated in a tumor cell by applying a specific carrier is irradiated by low thermal energy-neutrons. The captured neutron in boron produces alpha particle and Li ions ($^{10}$B (n,α) $^{7}$Li) (Fig.1) with a high level of linear energy transfer at tissue. So, it could be effective in killing tumor cells (Fig.2) [5]. Component BNCT that delivers boron selectively to the tumor cells is boron delivery agent. This agent must deliver enough of $^{10}$B to the tumor cell to sustain ($^{10}$B (n,α) $^{7}$Li ) capture reaction in order to damage tumor cell

---

¹ Corresponding author. E-mail address: sistawijaya@students.itb.ac.id
efficiently. Moreover, boron must stay in tumor cells for a length of time and stay clear from the surrounding normal cells. Ideally, the tumor to normal cell ratio is greater than 3-4:1 [6]. In clinical studies of BNCT, the two main boron-based drugs are sodium mercaptoundehydrododecarbonate (Na₂₁₀B₁₂H₁₁SH; Na₂¹⁰ BSH) and L-ρ-boronophenylalanine (L⁻¹⁰BPA) used for the treatment of malignant brain tumors and malignant melanoma [5]. BNCT has been focused on the treatment of malignant gliomas and until recently, head and neck and liver cancers. [13].

\[ ^4\text{He} + ^7\text{Li} + 2.79 \text{MeV (6\%)} \]
\[ \uparrow \]
\[ ^{10}\text{B} + n_{\text{th}} (0.025 \text{eV}) \rightarrow [^{11}\text{B}] \] (1)
\[ \downarrow \]
\[ ^4\text{He} + ^7\text{Li} + 2.31 \text{MeV (94\%)} \]
\[ \downarrow \]
\[ ^7\text{Li} + \gamma + 0.48 \text{MeV} \]

**Fig 1.** Nuclear reaction occurs in boron of BNCT [9]

**Figure 2.** Scheme application of BNCT in tumor cell [10]

2. MATERIALS AND METHODS

2.1 Boron Delivery Agent

The important requirements for a boron delivery agent in BNCT include the following: 1) concentration of boron in the tumor cell in the range of 20-35 µg per gram of the tumor cell and the ability to clear from the blood and normal cells relatively quickly, 2) low toxicity, and 3) selective to the tumor cell, can destroy only the tumor cells without affecting the healthy cells [7]. Based on previous study, development of a boron delivery agent taken three generations.

*First generation boron delivery agent*

In the 1950s and early 1960s, boric acid and its derivatives as delivery agents were first used in clinical trials. Currently, Boronophenylaniline (BPA) and (Polyhedral mercaptoborone) BSH are in Phase I and Phase II clinical trials, and both have a long history of preclinical studies. A third derivative is GB-10 that is currently being approved by the FDA [11.5]. These first generation of BPA and BSH, however, were to be poor at tumor retention, non-selective, toxic, and poor at penetrating tumor.

*Second generation boron delivery agent*

In 1960’s, the second generation of boron delivery agents BPA and BSH entered the clinical trials. They had low toxicity, longer retention of tumor cells, and a ratio of tumor: normal cell greater than 1 [10]. BPA is a boron compound containing neutral amino acid - phenylalanine. BPA’s structure is analogous to tyrosine as a precursor for synthesizing the pigment melanin. It was tested as a boron delivery agent of BNCT for malignant melanoma. Based on in vitro and in vivo test, BPA accumulated selectively in B16 melanoma cells [11]. Furthermore, BPA has more therapeutic effect than BSH based on clinical trials in the US, Finland, Sweden and Japan [6]. BPA is utilized for experimental study on brain tumor therapy. According to Codere et al.’s study, BPA is transported into rat gliosarcoma cells by a L-amino acids transporter system [2]. L-amino acids transporter system is highly expressed in brain tumor cells than in normal cells [14]. BPA has been mixed with fructose (L-BPA-F) in order to obtain high solubility in water and is improved with 10B [8].

BSH molecule that localize selectively in brain tumors and penetrates the disrupted blood brain barrier by passive diffusion. BSH couldn’t cross the intact BBB [8]. BSH doesn’t have specific transporter to the tumor, but BSH per molecule could carry molecule \(^{10}\text{B} 12\) times more than BPA [14]. In vitro, BSH accumulated in the cytoplasm and the nucleus of cells [11]. Otersen et al explains BSH has a negative charge by quaternary ammonium salts that can
bind to the positive charge of choline residues on phospholipids, which occur in membrane that contains phosphatidylcholine and spignomyeline. Choline is more highly expressed in tumor cells than in the white matter of normal cells [15].

*Third generation boron delivery agent*

A new number of boron delivery agents have been developed recently in order to deliver boron selectively to the target and to obtain a therapeutic concentration of boron [6]. Third generation boron delivery agents have better stability and selectivity than previous generations. The strategy to develop a boron delivery agent is incorporate it with a compound that has selectivity and specificity to the target such as peptides, proteins, antibodies, nucleosides, sugars, porphyrins, liposomes and nanoparticles [16].

3. RESULTS AND DISCUSSION

These are some of boron delivery agents with their current status.

<table>
<thead>
<tr>
<th>Boron Delivery Agent</th>
<th>Mechanism of Localization</th>
<th>Current status</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPA</td>
<td>Uptake by L-type amino acid transporters and cell membrane diffusion [20].</td>
<td>Clinical studies [17]</td>
</tr>
<tr>
<td>BSH</td>
<td>Accumulate in tumor cells by passive transport with the destruction of the blood brain barrier (BBB) [30].</td>
<td>Clinical studies [17]</td>
</tr>
<tr>
<td>Nucleoside and Carbohydrate Analog</td>
<td>Localize in tumor cells by kinase mediated trapping [24]. Thymidine kinase (TK1) is highly expressed in a tumor cell that is actively proliferating [22, 23].</td>
<td>Preclinical studies [22, 23]</td>
</tr>
<tr>
<td>Unnatural Amino Acids (ABCPC and ACBC)</td>
<td>Uptake by L-type amino acids transporters like phenylalanine [14].</td>
<td>Preclinical studies [14]</td>
</tr>
<tr>
<td>Cationic Polymers</td>
<td>Cationic polymer attracts to the anionic charge around the tumor cell that is expressed in sialic acid [27].</td>
<td>Preclinical studies [27]</td>
</tr>
</tbody>
</table>

| Porphyrin Derivatives | Accumulates in tumor cells via endosomal distribution and leaky vasculature [17]. | Preclinical studies [21] |
| Liposome             | Localizes in tumor cells via EPR effect [28]. Cationic liposomes attract the negative charge of the outer layer of mammalian plasma membranes by electrostatic interactions [29]. | Preclinical studies [28] |
| Nanoparticles        | Accumulate in tumor cells by their EPR (Enhanced Permeability and Retention) effect [31]. | Preclinical studies [31] |
| Monoclonal antibody  | Monoclonal antibody, like cetuximab, is attractive to and binds with EGF receptors or EGFRvIII, which are overexpressed in human glioblastomas [26]. | Preclinical studies [25, 26] |
| Cell Penetrating Peptides | Localize in tumor cells via electrostatic interaction with plasma membrane and penetrating by micropinocytosis [32]. | Preclinical studies [33] |

In Indonesia, the development of new boron delivery agents for BNCT focuses on healing common cancers such as ovarian, cervical, breast, thyroid, skin, and soft tissue cancers [34]. The faculty of Pharmacy Universitas Gadjah Mada have been developing a new boron delivery agent, pentagamaboronon-0 (PGB-0) which is curcumin analogous to that used for the treatment of breast cancer with positive HER2 [35]. The current status of PGB-0 is in preclinical studies and is expected going to clinical studies soon [36].

A number of clinical studies of new boron delivery agents for different varieties of tumor were reported in Europe, Asia and in the US in first decade of the 2000s [3]. Until now, there is no new boron delivery agents have progressed to clinical trials besides BPA and BSH [17]. They are stuck in in vitro and in vivo studies using animals. The reason is the lack of
promising in vitro and in vivo tests does not encourage the success of expensive clinical biodistribution studies in humans and even indicates that such studies could be harmful for the participating. There are many steps that are feasible in pre-clinical study but very difficult to implement in clinical studies [18].

Usually, evaluation reports of boron delivery agents are related to cytotoxicity, boron delivery agent uptake in vitro by model cell lines, time course biodistribution and analysis of boron in the tumor and in the blood for systemic toxicity. Biological study for every boron delivery agent is different depending on its synthesis and chemical characteristics. More data from biological studies is important for further development of boron delivery agents [19]. In BNCT, there is no specific standard protocol either in vitro/in vivo tests and clinical studies for dose treatment planning calculation and irradiation method. Every different research center has its own method [16]. The variety of evaluation data for boron delivery agents from different research centers causes difficulty when comparing evaluation data from center to center and also makes it difficult to go to the next evaluation step with a greater population of patients in clinical studies [19,16]. Clinical studies development of new boron delivery agents is slow also because of the absence of a readily available proper neutron source and the high cost [21].

Strategies to improve the number of new boron delivery agents through in vitro and in vivo tests rather clinical studies include the following: 1) establish centralized facility of biological evaluation for boron delivery agents including in vitro/in vivo tests and clinical studies which have proper laboratory facilities and instruments as well as a thermal and epithermal neutron source for irradiation experiment. The facility should also be staffed with personnel who are professionals in the biological aspect of BNCT. The centralization of biological work would provide better biological standards and more well-maintained cell and neutron sources to accumulate a more comprehensive database. 2) Encourage collaborative efforts between research centers to compare and determine standard dose prescriptions for further studies on greater populations or for randomized clinical trials. 3) Standard evaluation protocols for boron delivery agents must be adaptable to evaluate a variety of new boron delivery agents and new clinical objectives [19,16,9,11].

4. CONCLUSION AND REMARKS

BNCT is a potential treatment for healing cancer. In BNCT, a boron delivery agent is an important component to deliver boron to the tumor target. A number of boron delivery agents have been developed. But, to date, just two boron delivery agents are used in clinical studies, BSH and BPA. Therefore, some effort is required to improve the number of new boron delivery agents that could go through in vitro/in vivo test to clinical studies. So, BNCT could be used widely for cancer therapy.

ACKNOWLEDGMENT
The authors would like to thank to PSTA-BATAN for the opportunity to work on this research.

REFERENCES


Yang, W., Barth, R. F., Wu, G., Tjarks, W., Binns, P., & Riley, K. (2009). Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies

Indonesian Journal of Physics and Nuclear Applications
Volume 4, Number 2, June 2019, p. 39-44
e-ISSN 2550-0570, © FSM UKSW Publication
or epidermal growth factor as molecular targeting agents. *Applied Radiation and Isotopes*, 67(7-8 SUPPL.), 328–331. https://doi.org/10.1016/j.apradiso.2009.03.030


